Antigen‐specific efficacy varied: NF186 neuropathy resolved completely, while IgG4‐dominant paranodal cases (NF155/CNTN1) partially recovered, prompting sequential B‐cell‐targeted strategies. Here, CNTN1 is linked to neuropathy.